![AbbVie to buy Cerevel in $8.7B bet on brain drugs](https://www.biopharmadive.com/imgproxy/rHOJKoTXBUNFkemPmGhnc7G_UsjZwyO4inuu4hwEh3Q/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTk0MTM2MTA2Mi5qcGc.jpg)
AbbVie to buy Cerevel in $8.7B bet on brain drugs
AbbVie is restocking its drug pipeline in a big way, announcing Wednesday an $8.7 billion deal to buy neuroscience-focused Cerevel Therapeutics, just days after agreeing to a similar sized acquisition of the cancer biotechnology company ImmunoGen. Per the deal, AbbVie will pay $45 per share of Cerevel, which is developing medicines for schizophrenia, dementia and…